Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants

• Published in: Journal of translational medicine Vol. 14; no. 1; p. 296
• Main Authors: Cha, Yoon Jin, Kim, Hye Ryun, Shim, Hyo Sup
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 19.10.2016; BioMed Central
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - enzymology; Adenocarcinoma - genetics; Adenocarcinoma - pathology; Adenocarcinoma of Lung; Adult; Aged; Anaplastic Lymphoma Kinase; Cancer; Care and treatment; Chemotherapy; Clinical outcomes; Crizotinib; Diagnosis; Disease-Free Survival; Female; Gene Rearrangement - genetics; Humans; Kaplan-Meier Estimate; Lung cancer, Non-small cell; Lung Neoplasms - drug therapy; Lung Neoplasms - enzymology; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Male; Middle Aged; Mutation - genetics; Nucleic acids; Oncogene Proteins, Fusion - metabolism; Pemetrexed - therapeutic use; Proportional Hazards Models; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Pyrazoles - therapeutic use; Pyridines - therapeutic use; Pyrimidines - therapeutic use; Receptor Protein-Tyrosine Kinases - antagonists & inhibitors; Receptor Protein-Tyrosine Kinases - genetics; Sulfones - therapeutic use; Treatment Outcome; EML4-ALK fusion; Anaplastic lymphoma kinase inhibitor; Anaplastic lymphoma kinase; Pemetrexed; Non-small cell lung cancer

Clinical outcomes of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer according to ALK fusion variants are not clear. We aimed to investigate the prevalence of ALK fusion variants and to compare clinical outcomes according to ALK fusion variants. A retrospective analysis was co...